Vous trouverez sur cette page l’ensemble des études cliniques sponsorisés par Ipsen ou acquis par Ipsen. Vous pouvez utiliser le menu déroulant ci-dessous pour trouver des essais cliniques en sélectionnant un(e) ou plusieurs indications , statut d’étude, phase de l’étude ou pays participants.
Pour les études cliniques terminées pour lesquels les résultats sont disponibles , un résumé des résultats est accessible en cliquant sur le bouton « Lire le résumé » .
Vous pourrez aussi trouver un résumé scientifique des résultats sur les registres cliniques Europe et US.
Le ‘statut’ de recrutement des participants est défini comme suit :
- Not yet recruiting – Le recrutement n’a pas commencé
- Recruiting – Le recrutement est ouvert
- Enrolling by invitation – Le recrutement est ouvert à une population spécifique qui est invitée à participer
- Active, not recruiting – Le recrutement est fermé, Les participants sont toujours suivis dans l’étude
- Terminated – l’étude a été arrêtée prématurément
- Completed – l’étude est terminée
Last Data Refreshed @ 25-Jun-2025 03:23:07 UTC
Filtres
Condition
Statut
Phase
Country
Showing : 1 – 5 de 140 clinical trials
Follicular Lymphoma
Refractory Follicular Lymphoma
Tazverik
United States of America (the)
Not Yet Recruiting
A study to assess efficacy and safety of oral tazemetostat in adult participants with relapsed/refractory follicular lymphoma that does not have an “EZH2 gain-of-function” genetic mutation
The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an “EZH2” genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections, but when you have follicular lymphoma, the blood cells can form tumours in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. in your body. ‘Relapsed/refractory’ follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous – 5 – SM D form protocol master data -INT / Version 1 treatment. Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the “EZH2” mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an “EZH2” genetic mutation and who previously received therapies commonly used in the U.S. In this study, all participants will receive the study drug. It will be taken by mouth (orally), as a tablet, twice daily. The sizes and number of tumours according to scan results will be collected as well as results of safety tests (such as physical examinations and laboratory tests). The study consists of 3 or 4 periods: ? Screening period may take up to 4 weeks and require at least 1 visit. ? Treatment period will require 2 visits for each of the first 2 months, followed by 1 visit every month for the remainder of the first 6 months, followed by 1 visit every 3 months (except for women of childbearing potential [WOCBP], who will continue to have a visit every month) until unacceptable toxicity, disease progression, or the start of new systemic anticancer therapy, whichever is first. ? Safety follow -up period will last for 1 month after the last dose of tazemetostat, and it will end with 1 visit or telephone call. ? Long -term follow -up period is only for participants who stop taking tazemetostat while their disease continues to respond; this period will last until disease progression, start of new cancer treatment, or death from any cause, whichever is first. Tazemetostat will be provided to participants who tolerate it for as long as their disease does not progress. Participants may be transferred to another study or program after about 2 years for continued treatment with tazemetostat or for long-term follow-up. Patients may withdraw consent to participate at any time.
Cervical Dystonia
IPN10200
United States of America (the)
Not Yet Recruiting
A study of IPN10200 for the treatment of cervical dystonia in adults
The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating CD in adults. | Cervical dystonia can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. Cervical dystonia is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role. | The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period. | The study will consist of two periods:| (1) A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit. | (2) A Treatment Period of 36 weeks. | On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose D) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded. | There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose D). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study. | The total study duration for a participant will be up to 40 weeks (approximately 9 months).
Alagille Syndrome
Bylvay | Kayfanda
United States of America (the)
Poland
Belgium
Turkey
United Kingdom of Great Britain and Northern Ireland (the)
France
Germany
Italy
Malaysia
Netherlands (Kingdom of the)
Recruiting
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis). Detailed Description: This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS. The study will consist of 2 or 3 periods: A ‘Treatment period’ of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 ?g/kg odevixibat daily. An ‘Optional extension period’ where participants who wish to continue receiving odevixibat after the ‘treatment period’ will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor. A ‘Safety follow-up period’ of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period. Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.
Moderate To Severe Upper Facial Lines
IPN10200
Germany
France
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
The purpose of this study is to assess the safety and efficacy profile of increasing doses of IPN10200 in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines. This study will be conducted in three stages. The full study (including all stages) will have a maximum 448 participants. The protocol is currently approved up to stage 1, step 1 and stage 1/ step 2. Stage 1 (phase Ib & II) Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL) Step 2 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport Stage 2 (phase II) – An evaluation of efficacy and safety of IPN10200 in one of the following regions: GL + forehead lines (FHL) or lateral canthal lines (LCL) Stage 3 (phase II) – A safety and efficacy evaluation of IPN10200 in all three regions (GL, FHL and LCL)
Advanced Malignant Solid Tumor
Hepatic Impairment
Tazverik
United States of America (the)
Belgium
Poland
Slovakia
France
Recruiting
A study to compare the safety and blood levels of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver impairment to Participants with Advanced Cancer and Normal liver function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that is unlikely to be cured or controlled with treatment. The trial will also study the safety and the level that adverse effects of the study drug can be tolerated (known as tolerability).